Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
View Patent ↗The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 , R 22 , R 23 , and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.
1. A compound, or a pharmaceutically acceptable salt thereof, said compound having the general structure shown in Formula (I.a.10.j):
wherein: CB is a moiety selected from the group consisting of:
wherein each R 10 is independently selected from the group consisting of methyl, ethyl, and cyclopropyl;
X is N;
Y is N;
R 2 is H;
Z is selected from the group consisting of H, methyl, and chloro;
R is unsubstituted phenyl or phenyl substituted with from 1 to 4 substituents independently selected from the group consisting of alkyl, cycloalkyl, alkoxy, halo, —CN, —NH 2 , and —NO 2 ,
or, alternatively, R is unsubstituted heteroaryl or heteroaryl substituted with from 1 to 3 substituents independently selected from the group consisting of alkyl, alkoxy, cycloalkyl, halo, —CN, —NH 2 , and —NO 2 ; and
R 1 is selected from the group consisting of —NH 2 , —NHR 14 , and —NR 14 R 15 ;
each R 11 is independently selected from alkyl, alkenyl, haloalkyl, heteroalkyl, heterohaloalkyl, —S(O) 2 -alkyl, -alkyl-OH, —C(O)Oalkyl, —C(O)alkyl, —C(O)NHalkyl, —C(O)N(alkyl) 2 , cycloalkyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl;
each R 14 is independently selected from alkyl, alkoxy, alkenyl, haloalkyl, heteroalkyl, heterohaloalkyl, alkylamino, alkylthio, heteroalkenyl, haloalkenyl, —S(O) 2 -alkyl, -alkyl-OH, -alkyl-O-Acyl, —C(O)Oalkyl, —C(O)alkyl, cycloalkyl, cycloalkyl-alkyl-, heterocycloalkyl, heterocycloalkyl-alkyl-, heterocycloalkenyl, heterocycloalkenyl-alkyl-, aryl, aryl-alkyl-, heteroaryl, and heteroaryl-alkyl-,
wherein each said alkyl, each said alkoxy, each said alkenyl, each said haloalkyl, each said heteroalkyl, each said heterohaloalkyl, each said alkylamino, each said alkylthio, each said heteroalkenyl, each said haloalkenyl, each said —S(O) 2 -alkyl, each said -alkyl-OH, each said -alkyl-O-Acyl, each said —C(O)Oalkyl, each said —C(O)alkyl, each said cycloalkyl, each said cycloalkyl-alkyl-, each said heterocycloalkyl, each said heterocycloalkyl-alkyl-, each said heterocycloalkenyl, each said heterocycloalkenyl-alkyl-, each said aryl, each said aryl-alkyl-, each said heteroaryl, and each said heteroaryl-alkyl-, is unsubstituted or optionally independently substituted with from one to three substituent, which can be the same or different, each substitutent being independently selected from —OH, halo, —NH 2 , —NHR 10 , —NR 10 R 11 ,—C(O)OH, —C(O)OR 10 , —C(O)NHR 10 , —C(O)NR 10 R 11 , —S(O) 2 alkyl, —S(O) 2 aryl, alkyl, alkoxy, haloalkyl, haloalkoxy, heteroalkyl, heteroalkyl, heterohaloalkyl, aryl, cycloalkyl, and heterocycloalkyl;
each R 15 is independently selected from alkyl, alkoxy, alkenyl, haloalkyl, heteroalkyl, heterohaloalkyl, alkylamino, alkylthio, heteroalkenyl, haloalkenyl, —S(O) 2 -alkyl, -alkyl-OH, -alkyl-O-Acyl, —C(O)Oalkyl, —C(O)alkyl, cycloalkyl, cycloalkyl-alkyl-, heterocycloalkyl, heterocycloalkyl-alkyl-, heterocycloalkenyl, heterocycloalkenyl-alkyl-, aryl, aryl-alkyl-, heteroaryl, and heteroaryl-alkyl-,
wherein each said alkyl, each said alkoxy, each said alkenyl, each said haloalkyl, each said heteroalkyl, each said heterohaloalkyl, each said alkylamino, each said alkylthio, each said heteroalkenyl, each said haloalkenyl, each said —S(O) 2 -alkyl, each said -alkyl-OH, each said -alkyl-O-Acyl, each said —C(O)Oalkyl, each said —C(O)alkyl, each said cycloalkyl, each said cycloalkyl-alkyl-, each said heterocycloalkyl, each said heterocycloalkyl-alkyl-, each said heterocycloalkenyl, each said heterocycloalkenyl-alkyl-, each said aryl, each said aryl-alkyl-, each said heteroaryl, and each said heteroaryl-alkyl-, is unsubstituted or optionally independently substituted with from one to three substituent, which can be the same or different, each substitutent being independently selected from —OH, halo, —NH 2 , —NHR 10 , —NR 10 R 11 , —C(O)OH, —C(O)OR 10 , —C(O)NH 2 , —C(O)NHR 10 , —C(O)NR 10 R 11 , —S(O) 2 alkyl, —S(O) 2 aryl, alkyl, alkoxy, haloalkyl, haloalkoxy, heteroalkyl, heteroalkyl, heterohaloalkyl, aryl, cycloalkyl, and heterocycloalkyl;
or, alternatively, R 14 and R 15 are linked together with the nitrogen to which they are attached to form an unsubstituted or substituted 4- to 6-membered heterocycloalkyl.
2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N; Y is N;
R 2 is H;
Z is selected from the group consisting of H, methyl, and chloro;
R is unsubstituted phenyl or phenyl substituted with from 1 to 4 substituents independently selected from the group consisting of alkyl, alkoxy, halo, —CN, —NH 2 , and —NO 2 ,
or, alternatively, R is unsubstituted pyridyl or pyridyl substituted with from 1 to 3 substituents independently selected from the group consisting of alkyl, alkoxy, halo, —CN, —NH 2 , and —NO 2 ;
R 1 is —NH 2 ; and
CB is a moiety having a formula:
3. A compound selected from the group consisting of:
Compd
#
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition according to claim 4 , further comprising at least one additional therapeutic agent selected from the group consisting of: an HCV polymerase inhibitor, an interferon, a viral replication inhibitor, an antisense agent, a therapeutic vaccine, a viral protease inhibitor, a virion production inhibitor, an immunosuppressive agent, an antiviral antibody, a CYP-450 inhibitor, an antiviral booster, and an antiviral sensitizer.
6. A method, of treating a viral infection or a virus-related disorder comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound according to claim 1 , wherein said viral infection or virus-related disorder is an HCV infection.